3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations

MicroStockHub Investment Overview The biotech sector of the stock market is finishing 2023 on a high after what has been a difficult couple of years. Buoyed by a Big Pharma M&A spree - the globally recognized Pharmas AbbVie (ABBV) and Bristol-Myers Squibb (BMY) have respectively spent a total of $18.8bn acquiring antibody drug conjugate ("ADC") specialist ImmunoGen (IMGN) and neuroscience pioneer Cerevel Therapeutics, and $18.1bn acquiring Karuna Therapeutics (KRTX) and its highly rated schizophrenia dr ...